Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...

A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.